PCP
IONS icon

Perimeter Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Perimeter Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-21,233
Closed -$917K – 192
2014
Q1 		$917K Sell
21,233
-10,833
-34% -$525K 0.46% 109
2013
Q4 		$1.28M Sell
32,066
-22,103
-41% -$787K 0.63% 82
2013
Q3 		$2.03M Buy
+54,169
New +$1.62M 0.38% 124

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perimeter Capital Partners's IONS Position: Q2 2014 in Review

Perimeter Capital Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2014, closing a stake of 21,233 shares — an estimated $917K sold.

Perimeter Capital Partners first reported a position in IONS in Q3 2013 and held it in 3 quarters. The position peaked at $2.03M in Q3 2013. 238 funds tracked by Wall St. Rank hold IONS as of Q2 2014.

  • Perimeter Capital Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 21,233 Ionis Pharmaceuticals shares in Q2 2014, an estimated $917K.
  • Perimeter Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Perimeter Capital Partners's Ionis Pharmaceuticals position peaked at $2.03M in Q3 2013.
  • 238 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2014.

Based on Perimeter Capital Partners's 13F filing for Q2 2014, filed 12 Aug 2014.